A Search Service for Abbreviation / Long Form

â–  Abbreviation / Long Form : BT / breakthrough

[Related PubMed/MEDLINE]
Total Number of Papers: 18
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   BT  (>> Co-occurring Abbreviation)
Long Form:   breakthrough
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Preparation of a new high-efficiency resin deodorant from coal gasification fine slag and its application in the removal of volatile organic compounds in polypropylene composites. FS, FSD, PP, VOCs
2019 Performance of dry water- and porous carbon-based sorbents for carbon dioxide capture. CAC, CBC, MDW, NDW, PC, TCBC
2018 Epidemiology, practice patterns, and prognostic factors for candidemia; and characteristics of fourteen patients with breakthrough Candida bloodstream infections: a single tertiary hospital experience in Japan. ---
2018 Evaluation of a novel hollow fiber membrane technique for collection of 1,1-dimethylhydrazine in air. CCD, HF, LODs, LOQs, NIOSH, RSM
2018 Investigation of retention of undesirable organic matter from aqueous samples in stopped-flow dialysis procedures for inorganic anions. HA, IC, MWCO
2018 Retreatment with sofosbuvir/velpatasvir in cirrhotic patients with genotype-4 who failed a previous interferon-free regimen: a case series. CHC, GT, IFN, RAS, RBV, SOF, SVR, TF, VEL
2017 Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study. HCC, HCV, OST, PEG-IFN, RBV, SVR
2016 Efficacy and Tolerability of Pegylated Interferon and Ribavirin in Combination with Simeprevir to Treat Hepatitis C Virus Infections After Living Donor Liver Transplantation. HCV
2016 Retreatment of Chronic Hepatitis C Infection with Telaprevir : Turkey Experience. HCV
10  2014 Simulation of the breakthrough behavior of volatile organic compounds against sorbent tube sampler as a function of concentration level and sampling volume. AA, BA, BuAc, i-BuAl, IA, MEK, MIBK, PA, pX, ST, VA, VOC
11  2010 Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*. HCV, NR, NS5A, RT, SVR
12  2010 Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. CLV, HBV, RT
13  2010 Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation. CI, ETV-TP, ETVr, HBV, LVD, LVDr, OR, RT
14  2010 Non-response to previous interferon therapy and cirrhosis are risk factors for predicting breakthrough during lamivudine therapy in patients with chronic hepatitis B. CH, HBV, IFN
15  2006 Risk factors and outcome for breakthrough candidaemia in patients with cancer. ---
16  2005 Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy. HBsAg, HBV, NR
17  2001 Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. ---
18  1995 The breakthrough phenomenon during alpha-interferon therapy of chronic hepatitis C: incidence, management, and outcome. alpha-IFN, CHC, CR, MU